A database of consented, clinical-prescreened, genetically-characterised rare cancer patients to accelerate the delivery of precision medicine trials.
The RareCan platform uses liquid biopsies to generate genetic data not available in clinical practice, and screens patients against a panel of target tumour mutations being used across a portfolio of our clients’ development programmes. This is a subscription service, through which clients can access patients with the genetic mutations they are targeting while sharing the cost of patient identification and screening.
We founded RareCan because together we can increase treatment options for rare cancer patients.
We founded RareCan because together we can improve outcomes for people with rare cancers
We founded RareCan because together we can empower people with rare cancer
We founded RareCan because together we can increase the number of options and opportunities for people with rare cancers
Previous
Next
Our partners
We collaborate with partners across the healthcare system to support patients with rare cancers.
